PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1750 participants.

Also called NCT05934487

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 1,750 participants (planned count) (from the registry)
Sponsor
Endotronix, Inc. (from the registry)
Registry
  • NCT NCT05934487
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Ireland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05934487. Randomized; double masking; primary purpose diagnostic. Start 2023-11-29 (actual); primary completion 2028-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Condition
Heart Failure NYHA Class II
Condition
Heart Failure NYHA Class III
Condition
Heart Failure
Intervention (Device)
Cordella™ Pulmonary Artery Sensor System
Lead sponsor
Endotronix, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05934487
Content hash
5ef6e4cb290b729aba8e31fbee001753ce3fd79fea362b6ae11ba01b68a1e098